TriSalus Life Sciences (TLSI) announces the appointment of David Patience as Chief Financial Officer, effective July 1, 2025. Patience succeeds James Young, who stepped down for personal reasons effective May 30, 2025. Dan Giordano, Vice President of Finance for TriSalus, will serve as acting Chief Financial Officer during the transition period. Young remains available to the Company to support an orderly transition.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSI:
- Trisalus Life Sciences Q1 2025 Earnings Call Highlights
- TriSalus Life Sciences: Strategic Developments and Revenue Growth Drive Buy Rating
- TriSalus Life Sciences management to meet virtually with Lake Street
- TriSalus Life Sciences: Strong Financial Performance and Strategic Focus Drive Buy Rating
- TriSalus Life Sciences: Promising Growth Trajectory and Strategic Focus Justify Buy Rating